key: cord-0830012-ucfgtik2
authors: Caviedes, Iván; Soto, Rodrigo; Torres, Antoni
title: Pulmonary Angiopathy in Severe COVID-19: Physiological Conclusions Derived from Ventilatory Ratio?
date: 2021-01-15
journal: Am J Respir Crit Care Med
DOI: 10.1164/rccm.202009-3446le
sha: 6e4518281daed43de6d3dc24f5ce8ec1488fc80c
doc_id: 830012
cord_uid: ucfgtik2

nan

For instance, plasma is administered in the setting of hemorrhagic shock for its ability to improve hemostasis; thus, the idea of administering plasma to any patient with underlying hypercoagulability should be undertaken very watchfully. Depending on the methods for aiming at inactivating residual virus during the preparation of CP, the content of coagulation factors also may decrease, which would eventually blunt its procoagulant effects (4) . However, in the presence of an already stimulated coagulation pathway as demonstrated by Patel and colleagues (1) , even small amounts of residual coagulation factors in CP may potentiate the coagulation cascade in patients with COVID-19, representing a source of potential harm.

In our opinion, the progression of thrombosis should not be evaluated only as evidence of new pulmonary embolism, but it may result in worsening oxygenations and gas exchanges. This could be the result of thrombosis and progression of perfusion defects with further dilatation of peripheral lung vessels. Moreover, considering the systemic impact of the underlying hypercoagulability, administration of CP may worsen perfusion in other vital organs, potentially increasing, among others, risks of myocardial and cerebral ischemia. Thus, great caution is warranted in looking for specific adverse events related to CP in patients with COVID-19.

To add more uncertainty on the use of CP, its efficacy for the treatment of COVID-19 has been questioned by a Cochrane systematic review (5) . Moreover, according to another recent meta-analysis of randomized controlled trials at low risk of bias, administration of CP to patients with severe influenza has not been shown to reduce mortality, number of days in the ICU, or number of days on mechanical ventilation (6) .

In summary, we think the results of the study of Patel and colleagues greatly contribute to the definition of pathogenesis and clinical characteristics of COVID-19, but they are also of great value when considering potential therapeutic strategies and the right approach to control for their safety. New studies on CP in patients with COVID-19 should be encouraged to report the methods of preparation for CP. n Pulmonary Angiopathy in Severe COVID-19: Physiological Conclusions Derived from Ventilatory Ratio?

To the Editor:

We read with interest the article by Patel and colleagues (1) in which they describe imaging, functional, and hematological aspects in 39 patients with acute respiratory distress syndrome due to coronavirus disease (COVID-19). As the authors describe, ventilatory ratio (VR) was calculated in two opportunities, once at admission and once after computed tomographic scan, and it was increased in both. From that, they draw a conclusion about the presence of increased physiological respiratory dead space (VDphys/VT) based on a single surrogate parameter, the VR = (V : E 3 actual Pa CO 2 )/(predicted V : E 3 predicted Pa CO 2 ), where V : E represents actual minute volume. VR includes assumptions in normalizing data and does not consider CO 2 production (V : CO 2 ) as a variable (2) . Furthermore, VR was introduced as a simple bedside method to estimate efficiency of ventilation but not as a means to measure VDphys/VT (2) . Moreover, VR has not been validated under extracorporeal membrane oxygenation (ECMO) conditions (44% of patients at admission), so because of these reasons, those assumptions lessen support to their conclusion.

Important adjustments are included in the VR formula, where Pa CO 2 is controlled by the physician on the mechanical ventilator, and it excludes V : CO 2 . So, if a patient suffers changes in his inflammatory behavior, or in his spontaneous ventilatory efforts, the independent variable V : CO 2 will increase, but Pa CO 2 is controlled on the ventilator and will remain constant. In this case, V : E and VR increase but do not properly represent VDphys/VT. Even more, in patients under ECMO, Pa CO 2 specifically depends on the airflow in the oxygenating machine, and to the best of our knowledge, VR index has not been validated under this condition. The prognostic significance of VDphys/VT has been established in patients with acute respiratory distress syndrome, and the best available index of VDphys/VT is the Enghoff equation: (Pa CO 2 -PE CO 2 )/Pa CO 2 , in which mean expired partial pressure of CO 2 (PE CO 2 ) corresponds to the ratio between V Under this rationale, in a previous study of our group, in 43 patients on MV without ECMO, we evaluated the performance of common surrogate parameters in relation to VDphys/VT, also including VR. Patients were sedated and in stable condition. We tested the correlation between VDphys/VT and the following variables: VR, (Pa CO 2 2 Et CO 2 )/Pa CO 2 , Pa CO 2 2 Et CO 2 , and V :

where Et CO 2 represents end-tidal CO 2 .

Results demonstrated significant correlations between VDphys/VT and VR (r = 0.45), (Pa CO 2 2 Et CO 2 )/Pa CO 2 (r = 0.60), Pa CO 2 2 Et CO 2 (r = 0.63), and V 

To the Editor:

This letter is in response to an article published in a recent issue of the Journal by Patel and colleagues (1) . The authors' observation is consistent with a previous report, suggesting varying grades of pulmonary thromboembolism, pulmonary vascular microthrombosis, and pulmonary vascular dilatation in an advanced stage of acute hypoxemic failure owing to coronavirus disease (COVID-19) (1, 2) . In the current study, radiologic findings were obtained when nearly 50% of patients were on extracorporeal membrane oxygenation (ECMO). Therefore, interpretation and generalization of the findings becomes somewhat more intriguing because of complexities arising from hemodynamic, oxygenation, and hematologic alterations induced by ECMO (3). Venoarterial ECMO is known to increase afterload, left ventricular (LV) end diastolic pressure, left atrial pressure, and postcapillary venous dilatation. Furthermore, femoral arterial oxygenated flow may not reach the coronary circulation because of the watershed effect (north-south syndrome) and may induce LV ischemia and aggravate LV dysfunction (4). In addition, the venous return diversion to the ECMO circuit may induce stagnation in the pulmonary circulation, which may get further aggravated by an increase in pulmonary vascular resistance because of positive endexpiratory pressure. However, total lung-blood volume may get reduced and there is a lesser hydrostatic pressure gradient for pulmonary edema formation. Therefore, a reduction in dynamic compliance may be expected during venoarterial ECMO because of a fall in total pulmonary fluid volume. Undoubtedly, venovenous

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/). For commercial usage and reprints, please contact Diane Gern (dgern@thoracic.org).

Pulmonary angiopathy in severe COVID-19: physiologic, imaging, and hematologic observations

COVID-19 pneumonia: different respiratory treatments for different phenotypes?

Early safety indicators of COVID-19 convalescent plasma in 5

Plasma treated with methylene blue and light: clinical efficacy and safety profile

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review

Efficacy of convalescent plasma for the treatment of severe influenza

Pulmonary angiopathy in severe COVID-19: physiologic, imaging, and hematologic observations

Physiologic analysis and clinical performance of the ventilatory ratio in acute respiratory distress syndrome

Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome

Deadspace ventilation: a waste of breath!

Minute ventilation to carbon dioxide production ratio is a simple and non-invasive index of ventilatory inefficiency in mechanically ventilated patients: proof of concept